Anti-Aging Drug vs. Alzheimer's? (
The Catch? )
Rapamycin — a transplant rejection drug — increased brain blood flow in middle-aged APOE4 carriers after just 4 weeks. Women saw the biggest benefit. But it's a tiny pilot with no placebo.
- Claim
- TRANSPLANT DRUG VS ALZHEIMER'S
- Catch
- SINGLE-ARM
- Verdict
- A CLUE. NOT A PROTOCOL.
The study: Aware C, Neher CM, Woods C, et al. "Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: A pilot single-arm trial." Journal of Cerebral Blood Flow & Metabolism. 2026. DOI: 10.1177/0271678X261490342
What they did:
- Recruited healthy adults 45–65, with and without APOE4 (the strongest common genetic risk factor for Alzheimer's)
- Gave low-dose rapamycin daily for 4 weeks (single-arm, no placebo control)
- Measured cerebral blood flow (ASL-MRI), metabolic markers, inflammatory markers, gut microbiome
- APOE4 carriers showed significant cerebral blood flow increase; non-carriers did not
- Women with APOE4 showed the greatest improvement
- Also observed shifts in metabolism, inflammation, and microbiome profiles
The catch:
- Single-arm pilot — no placebo, no randomization, no control group
- ~20 participants total (exact n not in abstract), very small
- Only 4 weeks — zero data on long-term effects, cognitive outcomes, or Alzheimer's prevention
- Rapamycin risks: Immunosuppression (infections, poor wound healing), glucose intolerance, lipid abnormalities, mouth ulcers — at transplant doses; low-dose safety profile not established for chronic use
- APOE4 carriers only — no evidence for general population
- University of Missouri press release notes: "The study did not establish whether the treatment could prevent Alzheimer's or preserve memory over time"
SOURCES
- Aware C, Neher CM, Woods C, et al. Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: A pilot single-arm trial. J Cereb Blood Flow Metab. 2026. doi:10.1177/0271678X261490342
- University of Missouri-Columbia press materials
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Rapamycin is a prescription immunosuppressant with serious risks. Consult your physician before considering any off-label use. Alzheimer's prevention strategies should be discussed with a healthcare provider.
---
For information only, not medical advice. Talk to a qualified health professional before changing your diet, supplements or treatment.
THE CATCH BY EMAIL
Get the catch by email
One short email a week: the viral claims we checked, what the sources really say, and the catch. No spam, unsubscribe in one click.
Free. Sent through Buttondown. Privacy
